PainWASABINCT04653064
The Warmth, Anticipation, Sensation, Aversion, and Body-part Imaging Study
A study of Pain, run by Trustees of Dartmouth College at 1 site in United States.
Trial summary
This functional magnetic-resonance imaging study of the brain will feature a within-subject crossover design to investigate the effects of a placebo cream on painful thermal stimulation rendered upon eight body sites. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Pain
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 150 participants
- Where
- 1 siteUnited States
- Study dates
- 19 Mar 2021to 26 Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Subject must be a volunteer with a minimum age of 18 years and must be able and willing to provide written informed consent.
- If female, the subject must be non-lactating, not pregnant, and using a reliable contraception method.
- Subject must be able to read and speak English.
- Subject must be able to understand and follow the instructions of the investigator and understand all screening questionnaires.
- Subject must have no current or recent history of pathological pain.
- Subject must have abstained from alcohol and substance use for 48 hours.
- Subject must pass all fMRI screening tests.
Who cannot join
- If female, pregnancy.
- Inability to tolerate the scanning procedures (e.g., claustrophobia).
- Metal in body or prior history working with metal fragments (e.g., as a machinist).
- Inability to tolerate heat pain applied to the forearm.
- Reporting temporary abnormal levels of pain.
- Allergic response to the exfoliating cream.
Show all 36Show fewer
- Current presence of pain.
- Current or past history of psychoactive substance abuse or dependence.
- Dementias.
- Movement disorders except familial tremor.
- CNS infection.
- CNS vasculitis.
- Inflammatory disease or autoimmune disease.
- CNS demyelinating disease (e.g. multiple sclerosis).
- Space occupying lesions (mass lesions, tumors).
- Congenital CNS abnormality (e.g. cerebral palsy).
- Seizure disorder.
- History of closed head trauma with loss of consciousness.
- History of cerebrovascular disease (stroke, TIAs).
- Abnormal MRI (except changes accounted for by technical factors or UBOs.
- Neuroendocrine disorders (e.g., Cushings disease).
- Uncorrected hypothyroidism or hyperthyroidism.
- Current or past history of cancer.
- Recent history (within two years) of myocardial infarction, severe cardiovascular disease, or currently active cardiovascular disease (e.g. angina, cardiomyopathy).
- Uncontrolled hypertension or hypotension.
- Chronic pain syndromes.
- Chronic fatigue syndromes.
- A history of neurologic disease or neuropathic pain.
- Prior treatment within the last month with any of the following: antidepressants, mood stabilizers, glucocorticoids, opiates.
- Prior treatment with any of the following: antipsychotics, isoniazid, centrally active antihypertensive drugs (e.g. clonidine, reserpine).
- Any other contraindications for MRI examination (e.g., metallic implants such as pacemakers, surgical aneurysm clips, or known metal fragments embedded in the body).
- Current treatment for psychiatric disorders including mood, anxiety, substance abuse, attention-deficit/hyperactivity disorder (ADHD), psychosis.
- Neurological disorders (e.g., taking dopamine agonists for Parkinson's) Cardiovascular disease or medication (e.g., taking ACE (angiotensin-converting-enzyme) inhibitors for cardiac remodeling).
- Frequent smoking (> 5 cigarettes / day).
- Frequent alcohol use (> 14 drinks / week).
- Frequent migraines (> 5 / month on average).
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
Dartmouth College
Hanover, New Hampshire, 03755
Bethany Hunt, BA, bethany.j.hunt@dartmouth.edu
About this study
Official title: Placebo Effects on Anxiety and Pain
This functional magnetic-resonance imaging study of the brain will feature a within-subject crossover design to investigate the effects of a placebo cream on painful thermal stimulation rendered upon eight body sites. The investigators aim to 1.) improve the understanding of how the brain represents thermal pain responses somatotopically (i.e., across different body-sites) 2.) to test these brain representations with and without the presence of a pain-targeted placebo intervention, and 3.) to examine how these brain representations change prior to vs. during the delivery of thermal pain. They predict that placebo cream will downregulate the intensity of aversive brain activity representations, and to a lesser degree, sensation and somatotopic representations, both prior to and during painful thermal stimulation.
Read the detailed description
Background:
Pain is a significant problem within and outside of clinical contexts, and understanding the phenomenon is imperative for optimizing patient care and understanding the efficacy of pain treatment. At the same time, pain anxiety handicaps behavior and productivity, impedes the adoption of healthy behaviors and proper healthcare delivery, and is implicated in the development and maintenance of chronic pain disorders.
Pain is commonly perceived as a simplistic attention-capturing stimulus response homeostatic monitoring system that serves a tissue-protective function. Contemporary research, however, promotes a process model of pain that goes beyond simple transmission of a nociceptive signal from a transduced stimulus to include aspects of physiological modulation (e.g., regulatory brain activity from midbrain and brainstem, endogenous and exogenous opioids, and experiential perception (e.g., perceptual brain activity from S1, PFC, thalamus, S2, insula, and thalamus, perceptual exercises such as body vision. Clearly, accurate understanding of pain requires require combining signals across brain regions and networks Our lab, using machine-learning based multivoxel pattern analysis (MVPA) have trained several now widely-used whole-brain neural signatures for pain experience using thermal pain delivery devices (e.g., Neural Pain Signature [NPS]), as well as pain-related processes such as viewing pictures of others in pain (Vicarious Pain Signature [VPS]), and imagining being romantically rejected. Pursuit of this line of work has revealed these signatures are sensitive and specific to the type of pain it was developed for, yet generalizable enough to work in samples and pain modalities it was not developed in. For example, NPS is specific to somatic pain, and rises and falls with levels of somatic pain of many types, including thermal pain, mechanical pain, and electric shock, but does not track vicarious pain.
Our existing signatures do not respond to psychological changes in pain, which is believed to be necessary components for understanding pain hyper- and hypo-algesia as well as the placebo effect. The placebo effect is a powerful demonstration of the effects of the psychological pain context on pain experience. The effect may be directly attributable to emotional and attentional processing. Pain processing shifts from nociceptive somatosensory to emotional during chronification of pain and there is ample evidence that anxiety and stress modulate the amounts of pain reported, the degree of treatment and attention requested, and the degree of pain analgesia experienced upon application of placebo. This evidence suggests that aversive processing of incoming stimuli may play a role in the pain experience. Placebo effects may also simply be somatotopically attention driven, as one previous non fMRI study has suggested.
The basic mechanisms of placebo effects on pain anticipation and pain anxiety, and how they relate to placebo effects on pain, are still unknown. Understanding how each of subcomponents of pain -- theoretically separable as the detection of incoming sensation, aversive experiencing, and somatotopic location -- is affected by a placebo treatment may elucidate important facts about pain. This includes how pain is anticipated, processed, and subsequently regulated, providing insight into the nature of pain anxiety and how information should be delivered to mitigate pain. Such knowledge is essential for enhancing existing therapies and creating more nuanced and targeted ones for debilitating pain-related maladies such as chronic pain disorders, and important therapeutic procedures that may cause pain (e.g., surgical or dental).
Experimental Design:
The first hour of fMRI scanning aims to isolate sensation, aversiveness, and somatotopic subcomponents of pain into individual neural signatures. We will do so by subjecting participants at random to stimulations of painful heat and non-painful warmth on various body sites -- left and right masseter, midline chest, midline trunk, left and right forearm, and left and right upper-calf -- as well as listen to an aversive sound (e.g., scratching chalkboard). Participants will also be asked at various times to follow instructions to imagine themselves feeling intense heat pain at a randomly designated body site.
In the second hour of fMRI scanning, we will examine to what degree the identified isolated subcomponents of sensation, aversiveness, and somatotopy respond to placebo treatment for heat pain (i.e., the application of an inert cream coinciding with either an instruction that the participant will be given "an analgesic cream" relative to "a control cream with no effect").
- Conditions
- Pain
- Being tested
- Placebo Cream, Control Cream
- Medical subject headings
- Pain
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Placebo CreamBehavioural
Approximately 1 teaspoon of exfoliating skin scrub delivered approximately 5 minutes prior to pain tasks will coincide with verbal descriptors of the cream as being analgesic.
Control CreamBehavioural
Approximately 1 teaspoon of exfoliating skin scrub delivered approximately 5 minutes prior to pain tasks will coincide with verbal descriptors of the cream as one of no effect.
| Study group | Role | What they receive |
|---|---|---|
| Placebo Cream first | Experimental | Each participant will undergo thermal pain tasks after being administered a "treatment" cream to one of eight body sites. Receives: Behavioral: Placebo Cream; Behavioral: Control Cream |
| Control Cream first | Experimental | Each participant will undergo thermal pain tasks after being administered a "control" cream to one of eight body sites. Receives: Behavioral: Placebo Cream; Behavioral: Control Cream |
What is being measured
The primary outcome is the main question the study is designed to answer.
Contrasts of pain valence (i.e., unpleasantness) using the Bartoshuk Labeled Magnitude Scale (LMS) between body sites administered Placebo vs. Control Cream, both prior to and during pain delivery.
Self-reported pain valence using the LMS ranging from 0-10 (with 0 representing "no pain" and 10 representing "most unlikable pain of any kind experienced".
Measured: Hour 2 of fMRI scanning, immediately after each pain delivery trial.
Contrast of pain intensity using the Bartoshuk Labeled Magnitude Scale (LMS) between body sites administered Placebo vs. Control Cream, both prior to and during pain delivery.
Self-reported pain intensity using the LMS ranging from 0-10 (with 0 representing "not intense" and 10 representing "most intense pain of any kind experienced".
Measured: Hour 2 of fMRI scanning, immediately after each pain delivery trial.
Secondary outcomes (3)
Contrasts of activation of fMRI aversiveness signatures between trials where Placebo-cream-applied body sites are stimulated vs. trials where Control-cream-applied body sites are stimulated, both prior to and during pain delivery.
This will be collected with a Siemens 3T PRISMA.
Measured: Hour 2 of fMRI scanning, immediately after each pain delivery trial.
Contrasts of activation of fMRI sensation signatures between trials where Placebo-cream-applied body sites are stimulated vs. trials where Control-cream-applied body sites are stimulated, both prior to and during pain delivery.
This will be collected with a Siemens 3T PRISMA.
Measured: Hour 2 of fMRI scanning, immediately after each pain delivery trial.
Contrasts of activation of eight fMRI somatotopic signatures between trials where Placebo-cream-applied body sites are stimulated vs. trials where Control-cream-applied body sites are stimulated, both prior to and during pain delivery.
This will be collected with a Siemens 3T PRISMA. Eight signatures will include left and right masseter, left and right forearm, left and right calf, sternum, and abdomen.
Measured: Hour 2 of fMRI scanning, immediately after each pain delivery trial.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Dec 2020
- Study start19 Mar 2021
- Primary completion26 Feb 2026 (estimated)
- Study completion26 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for PainStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 150 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Trustees of Dartmouth College
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Tor Wager, Trustees of Dartmouth College
- Investigators
- Tor D Wager, PhD, Principal investigator, Dartmouth College
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04653064
- Sponsor's protocol ID
- 230135
- Acronym
- WASABI
- Status last verified
- Jan 2026
- First submitted
- 16 Nov 2020
- Last updated
- 14 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: All MRI and behavioral data will be submitted to the NIMH Data Archive (NDA) according to the terms and conditions outlined on their website (https://ndar.nih.gov/contribute\_data\_sharing\_regimen.html ) and with OpenFMRI. All training and test data and multivariate models will also be stored in http://neurovault.org/, an open-source neuroimaging data repository that can accommodate single subject images and metadata used for training multivariate models. We have recently built http://neuro-learn.org/, a new open-source platform for training, testing, and comparing brain models using data stored in Neurovault. All of our neural signatures developed in this project will be made freely available to everyone through this platform. All scripts developed to analyze data for this project will be made publicly available on Github (https://github.com/canlab/CanlabCore) at the time of publication of primary manuscripts.
Study at a glance
From the registry record, last updated by the sponsor on 14 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Placebo Effects on Anxiety and Pain
- ClinicalTrials.gov ID
- NCT04653064
- Acronym / sponsor ID
- WASABI / 230135
- Conditions
- Pain
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 150 participants (estimated)
- Lead sponsor
- Trustees of Dartmouth CollegeUniversity, hospital or other
- Study start
- 19 Mar 2021 (actual)
- Primary completion
- 26 Feb 2026 (estimated)
- Study completion
- 26 Dec 2026 (estimated)
- First posted
- 4 Dec 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This functional magnetic-resonance imaging study of the brain will feature a within-subject crossover design to investigate the effects of a placebo cream on painful thermal stimulation rendered upon eight body sites. The investigators aim to 1.) improve the understanding of how the brain represents thermal pain responses somatotopically (i.e., across different body-sites) 2.) to test these brain representations with and without the presence of a pain-targeted placebo intervention, and 3.) to examine how these brain representations change prior to vs. during the delivery of thermal pain. They predict that placebo cream will downregulate the intensity of aversive brain activity representations, and to a lesser degree, sensation and somatotopic representations, both prior to and during painful thermal stimulation.
Detailed description
Background:
Pain is a significant problem within and outside of clinical contexts, and understanding the phenomenon is imperative for optimizing patient care and understanding the efficacy of pain treatment. At the same time, pain anxiety handicaps behavior and productivity, impedes the adoption of healthy behaviors and proper healthcare delivery, and is implicated in the development and maintenance of chronic pain disorders.
Pain is commonly perceived as a simplistic attention-capturing stimulus response homeostatic monitoring system that serves a tissue-protective function. Contemporary research, however, promotes a process model of pain that goes beyond simple transmission of a nociceptive signal from a transduced stimulus to include aspects of physiological modulation (e.g., regulatory brain activity from midbrain and brainstem, endogenous and exogenous opioids, and experiential perception (e.g., perceptual brain activity from S1, PFC, thalamus, S2, insula, and thalamus, perceptual exercises such as body vision. Clearly, accurate understanding of pain requires require combining signals across brain regions and networks Our lab, using machine-learning based multivoxel pattern analysis (MVPA) have trained several now widely-used whole-brain neural signatures for pain experience using thermal pain delivery devices (e.g., Neural Pain Signature [NPS]), as well as pain-related processes such as viewing pictures of others in pain (Vicarious Pain Signature [VPS]), and imagining being romantically rejected. Pursuit of this line of work has revealed these signatures are sensitive and specific to the type of pain it was developed for, yet generalizable enough to work in samples and pain modalities it was not developed in. For example, NPS is specific to somatic pain, and rises and falls with levels of somatic pain of many types, including thermal pain, mechanical pain, and electric shock, but does not track vicarious pain.
Our existing signatures do not respond to psychological changes in pain, which is believed to be necessary components for understanding pain hyper- and hypo-algesia as well as the placebo effect. The placebo effect is a powerful demonstration of the effects of the psychological pain context on pain experience. The effect may be directly attributable to emotional and attentional processing. Pain processing shifts from nociceptive somatosensory to emotional during chronification of pain and there is ample evidence that anxiety and stress modulate the amounts of pain reported, the degree of treatment and attention requested, and the degree of pain analgesia experienced upon application of placebo. This evidence suggests that aversive processing of incoming stimuli may play a role in the pain experience. Placebo effects may also simply be somatotopically attention driven, as one previous non fMRI study has suggested.
The basic mechanisms of placebo effects on pain anticipation and pain anxiety, and how they relate to placebo effects on pain, are still unknown. Understanding how each of subcomponents of pain -- theoretically separable as the detection of incoming sensation, aversive experiencing, and somatotopic location -- is affected by a placebo treatment may elucidate important facts about pain. This includes how pain is anticipated, processed, and subsequently regulated, providing insight into the nature of pain anxiety and how information should be delivered to mitigate pain. Such knowledge is essential for enhancing existing therapies and creating more nuanced and targeted ones for debilitating pain-related maladies such as chronic pain disorders, and important therapeutic procedures that may cause pain (e.g., surgical or dental).
Experimental Design:
The first hour of fMRI scanning aims to isolate sensation, aversiveness, and somatotopic subcomponents of pain into individual neural signatures. We will do so by subjecting participants at random to stimulations of painful heat and non-painful warmth on various body sites -- left and right masseter, midline chest, midline trunk, left and right forearm, and left and right upper-calf -- as well as listen to an aversive sound (e.g., scratching chalkboard). Participants will also be asked at various times to follow instructions to imagine themselves feeling intense heat pain at a randomly designated body site.
In the second hour of fMRI scanning, we will examine to what degree the identified isolated subcomponents of sensation, aversiveness, and somatotopy respond to placebo treatment for heat pain (i.e., the application of an inert cream coinciding with either an instruction that the participant will be given "an analgesic cream" relative to "a control cream with no effect").
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Placebo Cream first | Experimental | Behavioral: Placebo Cream, Behavioral: Control CreamEach participant will undergo thermal pain tasks after being administered a "treatment" cream to one of eight body sites. |
| Control Cream first | Experimental | Behavioral: Placebo Cream, Behavioral: Control CreamEach participant will undergo thermal pain tasks after being administered a "control" cream to one of eight body sites. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Subject must be a volunteer with a minimum age of 18 years and must be able and willing to provide written informed consent.
- If female, the subject must be non-lactating, not pregnant, and using a reliable contraception method.
- Subject must be able to read and speak English.
- Subject must be able to understand and follow the instructions of the investigator and understand all screening questionnaires.
- Subject must have no current or recent history of pathological pain.
Key exclusion criteria (36 listed)
- If female, pregnancy.
- Inability to tolerate the scanning procedures (e.g., claustrophobia).
- Metal in body or prior history working with metal fragments (e.g., as a machinist).
- Inability to tolerate heat pain applied to the forearm.
- Reporting temporary abnormal levels of pain.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Placebo CreamApproximately 1 teaspoon of exfoliating skin scrub delivered approximately 5 minutes prior to pain tasks will coincide with verbal descriptors of the cream as being analgesic. | Behavioural | Control Cream first, Placebo Cream first |
| Control CreamApproximately 1 teaspoon of exfoliating skin scrub delivered approximately 5 minutes prior to pain tasks will coincide with verbal descriptors of the cream as one of no effect. | Behavioural | Control Cream first, Placebo Cream first |
Primary outcome
Contrasts of pain valence (i.e., unpleasantness) using the Bartoshuk Labeled Magnitude Scale (LMS) between body sites administered Placebo vs. Control Cream, both prior to and during pain delivery.
Time frame: Hour 2 of fMRI scanning, immediately after each pain delivery trial.
Self-reported pain valence using the LMS ranging from 0-10 (with 0 representing "no pain" and 10 representing "most unlikable pain of any kind experienced".
Contrast of pain intensity using the Bartoshuk Labeled Magnitude Scale (LMS) between body sites administered Placebo vs. Control Cream, both prior to and during pain delivery.
Time frame: Hour 2 of fMRI scanning, immediately after each pain delivery trial.
Self-reported pain intensity using the LMS ranging from 0-10 (with 0 representing "not intense" and 10 representing "most intense pain of any kind experienced".
3 secondary outcomes
Contrasts of activation of fMRI aversiveness signatures between trials where Placebo-cream-applied body sites are stimulated vs. trials where Control-cream-applied body sites are stimulated, both prior to and during pain delivery.
Time frame: Hour 2 of fMRI scanning, immediately after each pain delivery trial.
Contrasts of activation of fMRI sensation signatures between trials where Placebo-cream-applied body sites are stimulated vs. trials where Control-cream-applied body sites are stimulated, both prior to and during pain delivery.
Time frame: Hour 2 of fMRI scanning, immediately after each pain delivery trial.
Contrasts of activation of eight fMRI somatotopic signatures between trials where Placebo-cream-applied body sites are stimulated vs. trials where Control-cream-applied body sites are stimulated, both prior to and during pain delivery.
Time frame: Hour 2 of fMRI scanning, immediately after each pain delivery trial.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Jan 2026.
- Individual participant dataSharing planned: Yes. All MRI and behavioral data will be submitted to the NIMH Data Archive (NDA) according to the terms and conditions outlined on their website (https://ndar.nih.gov/contribute_data_sharing_regimen.html ) and with OpenFMRI. All training and test data and multivariate models will also be stored in http://neurovault.org/, an open-source neuroimaging data repository that can accommodate single subject images and metadata used for training multivariate models. We have recently built http://neuro-learn.org/, a new open-source platform for training, testing, and comparing brain models using data stored in Neurovault. All of our neural signatures developed in this project will be made freely available to everyone through this platform. All scripts developed to analyze data for this project will be made publicly available on Github (https://github.com/canlab/CanlabCore) at the time of publication of primary manuscripts.
Related trials for Pain
Not yet recruitingPhase 2
Investigating the Analgesic Potential of (2R,6R)-HNK in Acute Pain in Healthy Volunteers
Healthy Volunteers
Recruiting
US Guided EOI Block Versus ESPB for Postoperative Analgesia in Laparoscopic Cholecystectomy
Postoperative Pain
Recruiting
Intraligamentary vs Inferior Alveolar Nerve Block for Pulpitis: A Randomized Clinical Trial
Symptomatic Irreversible Pulpitis (SIP), Dental Pain
Active, not recruitingObservational study
The Effect of Single Lung Ventilation Duration and Intraoperative Brain Oxygenation on Cognitive Function and Postoperative Pain in Geriatric Patients
Thoracic Anesthesia, Geriatric Anesthesia
Recruiting
Tramadol Versus Morphine for Postoperative Pain Relief Following Laparoscopic Abdominal Surgery
Multimodal Analgesia, Tramadol
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Tor D Wager, PhD principal investigator
Dartmouth College
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study of Pain, run by Trustees of Dartmouth College at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 36 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 14 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Tor D Wager, PhD (603-646-2196, Tor.D.Wager@Dartmouth.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Contrasts of pain valence (i.e., unpleasantness) using the Bartoshuk Labeled Magnitude Scale (LMS) between body sites administered Placebo vs. Control Cream, both prior to and during pain delivery. (time frame: Hour 2 of fMRI scanning, immediately after each pain delivery trial.). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Jan 2026.